SAN DIEGO, April 26, 2018 /PRNewswire/ -- OncoSec
Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing
intratumoral cancer immunotherapies, will present a
trial-in-progress poster presentation from its global,
multi-center, registration-directed open-label Phase 2b clinical trial, PISCES/KEYNOTE-695, assessing
the OncoSec's investigational therapy, ImmunoPulse® IL-12
(intratumoral pIL-12 [tavokinogene telseplasmid or "tavo"] with
electroporation), and the approved anti-PD-1 therapy pembrolizumab,
in patients with unresectable metastatic melanoma who have
progressed or are progressing on an anti-PD-1 therapy. The poster
presentation will occur at the upcoming American Society of
Clinical Oncology (ASCO) 2018 Annual Meeting to be held on
June 1-5, 2018, in Chicago, IL.
Details of the poster presentation are as follows:
Abstract Title: Trial in progress: A phase 2 study of
intratumoral pIL-12 plus electroporation in combination with
intravenous pembrolizumab in patients with stage III/IV melanoma
progressing on either pembrolizumab or nivolumab treatment
(PISCES). (Abstract #TPS9601)
Session Title: Melanoma/Skin Cancers
Date and Time: Monday, June 4,
2018 1:15 PM - 5:45 PM CST
Location: McCormick Place, Chicago, IL
Further details on the poster presentation will be provided in
upcoming Company communications. For more information about this
conference, please visit: www.asco.org.
About PISCES (Anti-PD-1 IL-12 Stage III/IV Combination
Electroporation Study)
PISCES is a global, multicenter phase
2b, open-label trial of intratumoral
plasma encoded IL-12 (tavokinogene telseplasmid or "tavo")
delivered by electroporation in combination with intravenous
pembrolizumab in patients with stage III/IV melanoma who have
progressed or are progressing on either pembrolizumab or nivolumab
treatment. The Simon 2-stage study of intratumoral tavo plus
electroporation in combination with pembrolizumab will enroll
approximately 48 patients with histological diagnosis of melanoma
with progressive locally advanced or metastatic disease defined as
Stage III or Stage IV. The primary endpoint will be the Best
Overall Response Rate (BORR).
About OncoSec Medical Incorporated
OncoSec is a
biotechnology company developing DNA-based intratumoral
immunotherapies with an investigational technology,
ImmunoPulse®, for the treatment of cancer. ImmunoPulse
is designed to enhance the local delivery and uptake of DNA-based
immune-targeting agents, such as plasmid encoded IL-12
(tavokinogene telseplasmid or "tavo"). In Phase 1 and 2 clinical
trials, ImmunoPulse® IL-12 has demonstrated a favorable
safety profile, evidence of anti-tumor activity in the treatment of
various solid tumors, and the potential to reach beyond the site of
local treatment to initiate a systemic immune response. OncoSec's
lead program, ImmunoPulse IL-12, is currently in clinical
development for metastatic melanoma and triple-negative breast
cancer. The program's current focus is on the significant unmet
medical need in patients with melanoma who are refractory or have
relapsed on anti-PD-1 therapies. In addition to tavo, the Company
is also identifying and developing new immune-targeting agents for
use with the ImmunoPulse platform. For more information, please
visit www.oncosec.com.
CONTACT
Investor Relations:
Stern Investor Relations
Will O'Connor
Phone: (212) 362-1200
will@sternir.com
Media Relations:
Janine McCargo / David Schemelia
Tiberend Strategic Advisors, Inc.
Phone: 212-827-0020
jmccargo@tiberend.com
dschemelia@tiberend.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/oncosec-announces-pisceskeynote-695-trial-in-progress-poster-presentation-at-upcoming-asco-2018-annual-meeting-300636943.html
SOURCE OncoSec Medical Incorporated